Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd. (NRSN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: NeuroSense is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, primarily Amyotrophic Lateral Sclerosis (ALS). Its lead product candidate, PrimeC, is a fixed-dose combination of ciprofloxacin and celecoxib. The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric (USD in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,210) | $(10,107) |
| Operating Loss | $(9,902) | $(12,049) |
| Research & Development Expenses | $(5,698) | $(7,274) |
| General & Administrative Expenses | $(4,204) | $(4,775) |
| Cash and Cash Equivalents (Year End) | $3,378 | $2,640 |
| Net Cash Used in Operating Activities | $(10,135) | $(8,354) |
| Net Cash Provided by Financing Activities | $10,913 | $3,975 |
| Accumulated Deficit | $(36,660) | $(26,121) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $2.1 million year-over-year. R&D expenses declined by 21.6% (driven by lower subcontractor costs and share-based compensation), and G&A expenses declined by 11.9% (driven by lower share-based compensation and insurance costs).
- Financing Activity: Net financing cash flow increased significantly to $10.9 million in 2024 compared to $4.0 million in 2023, reflecting multiple capital raises including registered direct offerings, private placements, and an ATM program.
- Warrant Liability: In June 2024, the company amended warrant terms, resulting in the reclassification of a $1.4 million warrant liability to equity. This eliminated the volatility associated with fair value revaluation of these instruments in the income statement for the remainder of the year.
- Share Count: Outstanding ordinary shares increased from 15.4 million in 2023 to 23.2 million in 2024 due to equity issuances.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- PrimeC Development: The company reported positive 18-month data from the PARADIGM Phase 2b trial for PrimeC in ALS. Following FDA feedback, the company plans to submit a final protocol for a pivotal Phase 3 study in the first half of 2025, with enrollment expected to commence in the second half of 2025.
- Collaboration: In December 2024, NeuroSense entered into a binding term sheet with a leading global pharmaceutical company for the development and commercialization of PrimeC in certain key territories. The deal includes an upfront payment, Phase 3 funding, and milestone payments, though a definitive agreement is not yet finalized.
- Capital Needs: Management states that existing cash resources ($3.4 million) are insufficient to fund operations for at least 12 months from the date of the financial statement approval. Substantial additional financing is required to achieve goals.
Risks and Contingencies
- Going Concern: The financial statements include a "going concern" reference due to recurring losses and the need for additional financing. There is no assurance that capital will be available on acceptable terms.
- Geopolitical Risk: The company's headquarters and primary operations are in Israel. While operations have not been materially disrupted by the ongoing conflict since October 2023, escalation could adversely affect business, supply chains, and employee availability.
- Regulatory Risk: Success depends on obtaining regulatory approval for PrimeC via the FDA's 505(b)(2) pathway. Failure to meet regulatory requirements or adverse clinical trial results could halt development.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $3.4 million cash balance against the projected costs of the upcoming Phase 3 trial and general operations.
- Collaboration Terms: Monitor the finalization of the binding term sheet with the global pharmaceutical partner, specifically the size of the upfront payment and the extent of funding for the Phase 3 trial.
- Phase 3 Timeline: Confirm the submission of the Phase 3 protocol to the FDA in H1 2025 and the start of enrollment in H2 2025 as planned.
- Dilution: Assess the impact of recent and potential future equity issuances (including the Standby Equity Purchase Agreement with YA II PN, LTD.) on shareholder dilution.
- Geopolitical Exposure: Evaluate the company's contingency plans for operational continuity in Israel given the ongoing regional conflict.